Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2002

View Archived Issues

Rho kinase inhibitor attenuates agonist-induced contractions in arteriosclerotic human arteries

New use for Cozaar to be reviewed this week by advisory committee

Adenoviral delivery of A-FOS as a means of overcoming drug resistance

Aerosol delivery of p53 using PEI as a promising new therapy for lung cancer

Restoration of impaired angiogenesis in aging hearts with PDGF-AB provides cardioprotection

Thalidomide analogue with promising preclinical profile presented during 2002 AACR meeting

Phase I trial initiated for Cytovaxine in the prevention of P. aeruginosa infections

Initiation of phase III program for BBR-2778 in NHL

KRP-199: a highly potent, selective and water-soluble AMPA receptor antagonist

ChemBridge and Eisai enter drug discovery collaboration

Avidex licenses CD80 antagonists from Active Biotech

Data presented at AACR meeting on LMW inhibitor of PAI-1 discovered at Xenova

Alfacell provides Onconase update

Gene transfer therapy study for cystic fibrosis

Glutamate receptor function potentiators designed by Lilly

First patients enrolled in trial of Ampakine CX-516 in mild cognitive impairment

Novel factor VIIa inhibitors reported in recent patent

Japan Tobacco reveals new series that stimulates apo A-I production

Synthesis and evaluation of novel VLA-4 and/or LPAM-1 antagonists reported by Kaken

Piperidine PDE4 inhibitors claimed by Ono

Amgen tyrosine kinase inhibitors reportedly useful for cancer and stroke

Schering AG and Imaging Diagnostic Systems collaborate to improve breast cancer detection

First patients receive TA-1790 in ED study

LifeTime acquires Beta LT

MC-1 enters phase II cardioprotective trial

Phase II studies of TOCOSOL Paclitaxel initiated

PRE-703 moved to project status in anxiety

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...